Universal Genetic Testing for Cancer Risk Reduction

Recruiting now · Not applicable

Conditions studied: Genetic Testing

In brief

The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.

Key facts

Study ID

NCT06926816

Run by

NYU Langone Health

People needed

600

Starts

2025-03-04

Expected to finish

2027-12-31

Last updated by the study team

2026-03-02

Who can join

Age: 25 and older, up to 39. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Female patients between ages of 25-39 years at the time of visit
• Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol.

You may not qualify if…

• Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers
• Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable)
• History of bilateral salpingo-oophorectomy
• Visit related to pregnancy or immediately postpartum (within 2 weeks)

Where it is running

• NYU Langone Health — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.